Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457350 | 0.90 | NPC1 (0.45) | KMT2ANPC1PTGDR2SIGMAR1TMEM97 | |
| SCHEMBL5445015 | 0.89 | NPC1 (0.58) | KMT2ANPC1PTGDR2SIGMAR1TMEM97 | |
| SCHEMBL5456289 | 0.88 | MAPT (0.41) | KMT2ANPC1PTGDR2SIGMAR1TMEM97 | |
| SCHEMBL5446338 | 0.86 | KMT2A (0.52) | KMT2ANPC1PTGDR2SIGMAR1TMEM97 | |
| SCHEMBL5452310 | 0.86 | MAPT (0.45) | KMT2ANPC1PTGDR2SIGMAR1TMEM97 | |
| SCHEMBL5464302 | 0.85 | NPC1 (0.46) | KMT2ANPC1PTGDR2SIGMAR1TMEM97 | |
| SCHEMBL5453639 | 0.85 | NPC1 (0.48) | KMT2ANPC1PTGDR2SIGMAR1TMEM97 | |
| SCHEMBL5454903 | 0.85 | NPC1 (0.53) | KMT2ANPC1PTGDR2SIGMAR1TMEM97 | |
| SCHEMBL5446453 | 0.84 | NPC1 (0.51) | KMT2ANPC1PTGDR2SIGMAR1TMEM97 | |
| SCHEMBL5458214 | 0.84 | LMNA (0.50) | KMT2ANPC1PTGDR2SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | KMT2A 1271/4885NPC1 1664/4885PTGDR2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.